Skip to content

CapMan sells its holding in Swereco Group


CapMan Press Release – 2.10.2015 at 9.30 a.m. EEST

CapMan sells its holding in Swereco Group

Funds managed by CapMan have sold their holding in Swereco Group AB, a Swedish manufacturer of OTC products, to Karo Bio AB (publ). The transaction was completed on 1 October 2015.

“We are pleased with our investment in Swereco. During our ownership, Swereco has completed several key acquisitions, brought new and interesting products and designs to the OTC market and expanded sales to the other Nordic countries” comments Johan Bennarsten, responsible for the CapMan Life Science IV fund.

Funds managed by CapMan, including the CapMan Life Science IV fund, invested in Swereco AB in 2010 and owned 35.75% of the company’s equity prior to the transaction. CapMan Plc is a significant investor in the CapMan Life Science IV fund.

For more information, please contact:
Johan Bennarsten, CapMan Life Science, tel. +46 707 495 659


CapMan is one of the European leaders in the private equity industry. For more than 25 years, we have been developing companies and real estate and supporting their sustainable growth. We are committed to understanding the needs of our customers in an ever-changing market environment. Our objective is to provide attractive returns and innovative solutions for our investors and value adding services for professional investment partnerships, growth-oriented companies and tenants. Our entrepreneurial investment partnerships – Buyout, Real Estate, Russia and Credit – as well as our associated company Norvestia are responsible for investment activities and value creation. CapMan’s service business offering includes fundraising advisory services, purchasing activities and fund management services to both internal and external customers. CapMan has 100 private equity professionals and assets under management of €3.0 billion.

Swereco Group AB
Founded in 1973, Swereco develops and produces a range of products towards pharmacies and OTC market. Swereco recorded net sales of approx. €16.5 million in 2014. The company’s head office is in Stockholm with sales offices in Oslo and Copenhagen. Its products are also distributed in Finland, Germany, the UK and central Europe.

Karo Bio AB
Karo Bio is a pharmaceutical company that develop drugs for key medical needs and with the aim to create a balance between preclinical projects and products and projects closer to the market. The headquarters are based in Huddinge and the share is listed on Nasdaq Stockholm.